An open-label pilot study to evaluate the safety and tolerability of tacrolimus ointment 0.1% for the treatment of keloids

Cosmetic Dermatology

Volumn 18, Issue 6, 2005, Pages 399-404

  Berman, Brian ^a   Poochareon, Varee ^a   Villa, Adriana M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; ESTHETICS; EVALUATION; FEMALE; FLU LIKE SYNDROME; GENERAL CONDITION IMPROVEMENT; HUMAN; KELOID; MALE; OPEN STUDY; PAIN; PATIENT SATISFACTION; PILOT STUDY; PRURITUS; SKIN BURNING SENSATION; UPREGULATION;

EID: 20444366187     PISSN: 10413766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Shaffer JJ, Taylor SC, Cook-Bolden F. Keloidal scars: a review with a critical look at therapeutic options. J Am Acad Dermatol. 2002;46(suppl 2):S63-S97.
2. Berman B, Flores F. Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alfa-2b injections. J Am Acad Dermatol. 1997;37(5 pt 1): 755-757.
3. Kim A, Dicarlo J, Cohen C, et al. Are keloids really "gli- loids"? high-level expression of gli-1 oncogene in keloids. J Am Acad Dermatol 2001;45:707-711.
4. Ladin DA, Hou Z, Patel D, et al. p53 and apoptosis alterations in keloids and keloid fibroblasts. Wound Repair Regen. 1998; 6:28-37.
5. Louro ID, McKie-Bell P, Gosnell H, et al. The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin. Cell Growth Differ. 1999;10:503-516.
6. Flores J, Berman B, Burdick A, et al. The effectiveness of a new method for assessing induration. J Am Acad Dermatol. 1998;39:1021-1022.